Member Info for Chris0123

"Emotional" Micky, what YOU, never!!!!

Hope your shares end up in a better position than your local football team Micky, for all our sakes.

No worries Haywain.

Feel like a Teacher's Pet, OH SH*T! Gonna get bullied now!

I was reading a study into 3 approved CD-19 directed CART products for B-cell non-Hodgkin lymphoma (LBCL)approved by the FDA each showcasing significant efficacy but not without toxicity risks, mandating patients to stay in close proximity to the treatment centre for 4 weeks (this is not unique to Hemogenyx). There was a retrospective study of 475 patients between 2018-2023 who were infused by one or other of the 3 therapies. Onset, after CAR T infusion, of CRS (cytokine release syndrome) in days 8-14 was observed in 5.4% of patients at risk. There were no cases recorded after 14 days. The median time for onset of CRS for all patients was 3 days (Haywain is saying this) with no significant differences between the 3 therapies being researched. Even incidents of more than a 3 Grade CRS was just 5% in all patients and the median for this level was onset in 6 days. We are well past that time zone also. Again the research showed no significant difference between the 3 products. The median time for resolution of CRS (if they got it) for all patients was 4 days (we are well past that time too). HG-CT-1 is 3rd generation. The research was the first to provide granular insights into the occurrence and severity of CRS and ICANS ( immune effector cell-associated neurotoxicity syndrome) beyond 2 weeks after CAR T infusion and during extended follow-up. Data suggests that, beyond 2 weeks, onset of CRS & ICANS after approved CD19 CAR T for LBCL is rare. A different treatment but CAR T infusion all the same. I think we are through the high-risk period and even if these conditions occurred they can be treated. Safety now sorted perhaps! On to "efficacy" next. No expert but a reader what experts have written. GLA

Thanks for your input Haywain. Can't say I understood the article fully but enough to know we've got something

Take the time to read the link. It's a commentary on Hemo's CAR T clinical trial from a qualified source with a decisive response from Vlad.

Https://www.linkedin.com/comm/feed/update/urn:li:activity:7300526347481677825?origin=NETWORK_CONVERSATIONS&lipi=urn%3Ali%3Apage%3Aemail_email_network_conversations_01%3BKBvbA8vgQIaMrSahZTUxqw%3D%3D&midToken=AQFSnuDuvdpyig&midSig=2uszWjRZuMNbE1&trk=eml-email_network_conversations_01-network~post-0-wrapper~link&trkEmail=eml-email_network_conversations_01-network~post-0-wrapper~link-null-3p3qjv~m7tj6y7q~yz-null-null&eid=3p3qjv-m7tj6y7q-yz&otpToken=MTAwNzFkZTUxNDJkY2FjNGIzMjQwNGVkNDIxZmU3Yjc4YWM2ZDY0ODlhYWM4ODYxNzJjZjAzNmQ0ZjViNTRmNmZjOGZkNGIyNTZmMGM3ZDU3YzVjNTI0Zjg5YzM4ODE3MTNkNDM1ZTEwNWZkOWZiNDg1LDEsMQ%3D%3D

March is fast approaching for 2nd site treatment of children. Improving the cash runway for this trial will naturally feed into the 2nd site progress. On we tread,!

Tuan6 yes, we know you have done your bit for lobotomy research over the years.

Hi Micky everyone is trying to navigate a pathway with their investments. Some are more content and confident than others with feelings often driven by research and study. You are bound to be frustrated if you simply flail your arms about expecting someone else to give you answers. I am sure that if you did some research yourself you might feel somewhat better about your own investment.Good luck and sincerely meant.

PP you have made the same statement over each of the last 3 days at least. How low do you need it to go before you buy in. Let's get it out there!

Great observation and summary Hulver.

No adverse news this week = good news in the midst of clinical trials

Roll on next week.

Deed Poll must have rejected Stu's application for a name change to Peterpharma and put a hold on it. In my view it will be several months before the hold on his name will be lifted. I think weeks to change his name is optimistic and just wanton ramping. Furthermore, he will need money to make the re-application and he will need to do a diluting raise from his preferred namesake Peterhouse.

Took the opportunity to listen again to the Interactive Investor interview with Hemogenyx, you know, the one Vlad said "listen to the interview, listen carefully". He stated "clear interest" & "growing interest" in their CAR T programme by big pharma. As well as physician team at the proposed 2nd site in the East "eager to push it (CAR T) forward" for pediatric trials Hemogenyx say they are preparing for. GL one and all.

Time will tell but, and it has been said before, the experts at the 2nd site will have seen the data and this is what is making the "eager" to advance trials for children. Clear signs that the experts are looking beyond the here and now trials and are already manoeuvering to expand the clinical trials to babies needing this potentially life-saving treatment. There are 5-7 cases of AML per million population per year - USA population 335 M = average 2010 cases per year in US alone. Imagine that, potentially saving that many babies & kids per year and we have a small part in identifying and having faith in the the company and it's people that might just deliver that cure. No wonder there is a "growing interest" from "big Pharma".

You have a good memory Hulver, it was I. Thank you for finding and sharing. GL

I asked for that Hiki.

Thought this was worth another read since it was the breakthrough point for HEMO CAR T, what we have in clinical trials now.

RNS from 20th February 2020

https://hemogenyx.com/announcements/car-t-cells-are-effective-against-aml-in-vivo/

Hemogenyx "....have obtained HIGHLY ENCOURAGING RESULTS

Tried to find the Mouse video - can anyone help? GLA

Investors are not scientists largely, so all you need worry about is whether top scientists, expert in this field, think it has enough legs to give it a go on a real life patient and children at some stage too. Oh, I think we tick that box already.

You can bet your bottom dollar the selected patient is interested too. Be patient peeps!

The "seminal" Patent for CBR was submitted on 16th March 2022 so we are nearing the 3rd Anniversary in exactly 2 months.

Appreciate these things take time and lots of facets to CBR but a timely update 1st Qtr as we awaite CT outcomes for CAR T would be very welcome.